Physician profile
Kumar S Desai
NPI 1841495728
$3,122.22
in general payments reported to CMS, 2019-2025
23 companies · $523 in 2025
The $523 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $266 · 2020: $321 · 2021: $263 · 2022: $489 · 2023: $404 · 2024: $856 · 2025: $523.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,696 · Education: $86.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,695.75 |
| Education | $86.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $431.54 | 2019-2023 | |
| Janssen Biotech, INC. | $354.23 | 2022-2025 | Stelara, Simponi Aria, Simponi |
| Conmed Corporation | $253.25 | 2022-2023 | Conmed Biliary |
| Celltrion USA INC. | $239.54 | 2024-2025 | Vegzelma, Zymfentra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $224.16 | 2020-2024 | Xifaxan |
| Regeneron Healthcare Solutions, INC. | $212.55 | 2023-2025 | Dupixent |
| Abbvie INC. | $205.64 | 2019-2025 | Linzess, Viberzi, Rinvoq |
| Phathom Pharmaceuticals, INC. | $165.39 | 2024-2025 | Voquezna |
| Avanos Medical | $142.07 | 2022 | |
| Janssen Scientific Affairs, LLC | $128.31 | 2025 | Tremfya |
| Pacira Pharmaceuticals Incorporated | $125.00 | 2024 | Exparel |
| E.R. Squibb & Sons, L.L.C. | $113.48 | 2021 | |
| Endogastric Solutions, INC | $112.06 | 2024 | Esophyx |
| Genzyme Corporation | $86.94 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $54.57 | 2022-2025 | Entyvio |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $48.79 | 2021-2022 | |
| Gilead Sciences, INC. | $43.92 | 2021-2022 | |
| Pfizer INC. | $38.70 | 2022-2023 | |
| Braintree Laboratories, INC. | $38.13 | 2023 | Suflave |
| Ethicon US, LLC | $37.09 | 2019 | |
| Organon LLC | $26.58 | 2024 | |
| Novo Nordisk INC | $21.40 | 2025 | Wegovy |
| W. L. Gore & Associates, INC. | $18.88 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kumar Desai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.